The Risk-Benefit Dialogue: Sharing Decisions on Treatment and Considering Toxicity in High-Risk, Clinically Localized Prostate Cancer

View at publisher Summarise with VIRAT
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

For high-risk, clinically localized prostate cancer—a condition in which treatment choice is strongly driven by toxicity considerations—studies demonstrate wide variation in how clinicians describe side effects, often resulting in failure to mention or quantify information about potential harms. Without structured and transparent discussions, patients cannot fully engage in shared decision-making, and treatment regret and dissatisfaction are more likely. Data strongly support the meaningful impact of toxicity discussion during SDM on patient consultations.

Fields of Study & Subjects

Patient-Provider Communication in Healthcare Prostate Cancer Diagnosis and Treatment Palliative Care and End-of-Life Issues

Publication details

Journal / source
Default Digital Object Group
Publication date
26 March 2026
Language
EN
Document type
Dataset